This week in drug discovery (1-5 May)

News round-up for 1-5 May by DDW Digital Content Editor Diana Spencer.

My five stand-out news headlines this week all relate to immunotherapy or immunomodulatory therapies for cancer, particularly advances in our understanding of how other factors in the body, i.e., vitamin D levels and the gut microbiome, can impact the patient’s response to treatment.

To learn more about where the future opportunities in immunotherapy will be found, register for DDW’s free webinar on May 10 – details below.

The top stories:

Vitamin D levels impact response to immunotherapy in melanoma

New research indicates that for patients with advanced skin cancer, it may be important to maintain normal vitamin D levels when receiving treatment with immune checkpoint inhibitors.

iOnctura expands pipeline and receives development grant

iOnctura, a clinical-stage biotech developing selective cancer therapies against targets that play critical roles in multiple tumour survival pathways, has exercised an exclusive option with Clavius Pharmaceuticals, adding the novel oral TGF-β pathway inhibitor, IOA-359, to its pipeline.

Gut microbes alter the body’s response to immunotherapy

New research in mice has identified how gut bacteria alter the body’s response to PD-1 checkpoint blockade immunotherapy, currently used for the treatment of 25 forms of cancer.

Eterna acquires Exacis’ allogeneic immuno-oncology platform

Eterna Therapeutics, a life science company focused on mRNA cell engineering, has acquired Exacis Biotherapeutics’ immuno-oncology platform.

The future of cancer immunotherapy: exclusive webinar

Hosted by DDW and supported by BPS BioScience and AcroBiosystems, ‘Cancer immunotherapy – where will the future opportunities be?’ will be free to attend on May 10. Join this free webinar to learn about the biggest opportunities for the future of cancer immunotherapy.

Related Articles

Join FREE today and become a member
of Drug Discovery World

Membership includes:

  • Full access to the website including free and gated premium content in news, articles, business, regulatory, cancer research, intelligence and more.
  • Unlimited App access: current and archived digital issues of DDW magazine with search functionality, special in App only content and links to the latest industry news and information.
  • Weekly e-newsletter, a round-up of the most interesting and pertinent industry news and developments.
  • Whitepapers, eBooks and information from trusted third parties.
Join For Free